Myristoylation of LMCD1 Leads to Its Species-Specific Derepression of E2F1 and NFATc1 in the Modulation of CDC6 and IL-33 Expression During Development of Vascular Lesions.

CONCLUSIONS: Together, these observations reveal that LMCD1 acts as an activator and repressor of E2F1 and NFATc1 in humans and mice, respectively, in the induction of CDC6 and IL-33 expression during development of vascular lesions. Based on these findings, LMCD could be a potential target for drug development against restenosis and atherosclerosis in humans. PMID: 32160773 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32160773?dopt=Abstract

Source: Arteriosclerosis, Thrombosis and Vascular Biology - March 11, 2020 Category: Cardiology Authors: Govatati S, Pichavaram P, Janjanam J, Guo L, Virmani R, Rao GN Tags: Arterioscler Thromb Vasc Biol Source Type: research